Last reviewed · How we verify
Autologous micro-fragmented adipose tissue
At a glance
| Generic name | Autologous micro-fragmented adipose tissue |
|---|---|
| Also known as | Lipogems |
| Sponsor | Kessler Foundation |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Expected minor adverse event
Key clinical trials
- Treatment of Crohn's Complex Perianal Fistulas With Tissue Transplantation by Local Injection of Micro-fragmented Autologous Adipose Tissue. (NA)
- Treatment of Osteoarthritis of the Hip Joint With Intra-articular Injection of Microfractured Autologous Adipose Tissue Containing Mesenchymal Stromal Cells. (NA)
- The Effect of Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis (PHASE3)
- Treatment of Symptomatic Bilateral Knee Osteoarthritis: Intra-articular Injection of Autologous Microfragmented Adipose Tissue and Hyaluronic Acid vs Intra Articular Injection of Autologous Microfragmented Adipose Tissue (NA)
- The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis (PHASE1)
- Therapeutic Effect of Microfragmented Adipose Tissue (Lipogems) Injection on Maximum Interincisal Opening Versus Injectable Platelet-rich Plasma (PRP) for the Treatment of Anterior Disc Displacement With Reduction : A Randomized Clinical Trial (PHASE2, PHASE3)
- Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis. (NA)
- Ultrasound-Guided Injections for Meniscal Injuries in Active-Duty Military (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: